Breaking News, Collaborations & Alliances

Merck, XtalPi Partner to Optimize Drug Formulations with AI-Powered Techniques

Joint study showcases the synergy between experimental expertise and advanced computational methods in drug development.

Merck and XtalPi Inc., a pharmaceutical technology company powered by artificial intelligence (AI) and automation, jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development. Traditional methods like milling and micronization, used to address undesirable crystal morphologies, can be disruptive and costly. Molecular dynamics simulations offer valuable insights for better crystallization experiment designs. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters